Explanation of contraindications for the use of entacapone/cordan

Entacapone is a COMT inhibitor commonly used in the treatment of Parkinson's disease. Its core function is to delay the peripheral metabolism of levodopa, thereby prolonging the drug's efficacy. However, these drugs are not suitable for all patients. Understanding contraindication groups is particularly critical to ensuring treatment safety and reducing side effects. According to the instructions and treatment guidelines, entacapone should be used with caution or even avoidance in many groups of people to reduce potential risks.

First, the clearest contraindications are patients with known hypersensitivity to Entacapone or any of its excipients. Once allergic reactions such as rash, difficulty breathing, and sudden drop in blood pressure have occurred due to this drug, continued use may have serious adverse consequences, so it must be strictly avoided. In clinical classification, such contraindications are absolute contraindications.

Secondly, patients with liver damage require special attention. Entacapone is metabolized in the liver. Overseas literature clearly states that patients with moderate to severe liver dysfunction should not use this drug to avoid increased concentrations due to limited drug metabolism, thereby increasing the risk of adverse reactions, such as severe gastrointestinal discomfort, hypotension, or exacerbation of exercise complications. Patients with mild liver impairment need to be carefully evaluated under medical supervision.

Third, patients taking certain antidepressants (such as non-selective monoamine oxidase inhibitors MAOIs) are also contraindicated. The reason is that the combination of Entacapone and MAO inhibitors may excessively affect catecholamine metabolism, leading to abnormal blood pressure or even severe autonomic nervous system reactions. If the patient must be treated for depression at the same time, the doctor should switch to another safer antidepressant drug regimen.

In addition, patients with active malignancies, a history of certain cardiac conditions, and a tendency toward severe hypotension often require careful evaluation, as entacapone may increase levodopa concentrations and induce certain drug-related complications.

Reference materials:https://www.drugs.com/mtm/comtan.html